State Street Corp Boosts Stock Holdings in AbbVie Inc. $ABBV

State Street Corp lifted its position in AbbVie Inc. (NYSE:ABBV) by 1.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 82,596,748 shares of the company’s stock after acquiring an additional 1,379,232 shares during the quarter. State Street Corp’s holdings in AbbVie were worth $20,784,646,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Geode Capital Management LLC boosted its holdings in AbbVie by 10.4% during the fourth quarter. Geode Capital Management LLC now owns 44,629,980 shares of the company’s stock worth $10,179,099,000 after purchasing an additional 4,190,487 shares during the last quarter. Norges Bank purchased a new stake in AbbVie in the 4th quarter valued at about $5,865,055,000. Capital Research Global Investors lifted its position in shares of AbbVie by 0.7% during the 4th quarter. Capital Research Global Investors now owns 25,408,200 shares of the company’s stock worth $5,805,530,000 after buying an additional 177,370 shares in the last quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its stake in shares of AbbVie by 0.7% in the 2nd quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 14,267,697 shares of the company’s stock worth $3,590,323,000 after buying an additional 106,091 shares during the last quarter. Finally, Franklin Resources Inc. boosted its stake in shares of AbbVie by 2.3% in the 4th quarter. Franklin Resources Inc. now owns 14,881,504 shares of the company’s stock worth $3,400,274,000 after buying an additional 330,104 shares during the last quarter. Hedge funds and other institutional investors own 70.23% of the company’s stock.

Analyst Ratings Changes

ABBV has been the subject of a number of research analyst reports. Royal Bank Of Canada increased their price target on AbbVie from $260.00 to $280.00 and gave the company an “outperform” rating in a research report on Friday, July 10th. Erste Group Bank raised AbbVie from a “hold” rating to a “buy” rating in a research report on Wednesday, August 5th. Weiss Ratings upgraded AbbVie from a “hold (c)” rating to a “buy (b-)” rating in a research note on Tuesday, August 4th. HSBC raised their target price on AbbVie from $300.00 to $315.00 and gave the company a “buy” rating in a research report on Thursday, September 10th. Finally, Guggenheim boosted their price target on shares of AbbVie from $261.00 to $288.00 and gave the stock a “buy” rating in a report on Tuesday, August 4th. Two equities research analysts have rated the stock with a Strong Buy rating, eighteen have issued a Buy rating and five have issued a Hold rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $276.64.

AbbVie Stock Up 0.4%

Shares of ABBV stock traded up $1.03 during trading on Tuesday, hitting $265.51. The company had a trading volume of 892,624 shares, compared to its average volume of 6,538,061. The stock’s 50-day moving average is $255.90 and its two-hundred day moving average is $232.37. The stock has a market capitalization of $469.11 billion, a price-to-earnings ratio of 75.07, a price-to-earnings-growth ratio of 1.19 and a beta of 0.29. AbbVie Inc. has a 52 week low of $190.75 and a 52 week high of $267.47.

AbbVie (NYSE:ABBV) last announced its earnings results on Friday, July 31st. The company reported $3.65 earnings per share (EPS) for the quarter, beating the consensus estimate of $3.61 by $0.04. The business had revenue of $16.99 billion during the quarter, compared to analyst estimates of $16.80 billion. AbbVie had a net margin of 9.80% and a negative return on equity of 422.07%. AbbVie’s revenue for the quarter was up 10.2% on a year-over-year basis. During the same period in the previous year, the business posted $2.97 earnings per share. AbbVie has set its Q3 2026 guidance at 3.840-3.880 EPS. On average, research analysts predict that AbbVie Inc. will post 14.05 EPS for the current fiscal year.

AbbVie Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Monday, November 16th. Investors of record on Thursday, October 15th will be given a $1.73 dividend. The ex-dividend date is Thursday, October 15th. This represents a $6.92 annualized dividend and a yield of 2.6%. AbbVie’s payout ratio is 195.48%.

Insider Buying and Selling

In related news, EVP Nicholas Donoghoe sold 32,710 shares of the stock in a transaction on Friday, August 14th. The stock was sold at an average price of $250.00, for a total value of $8,177,500.00. Following the transaction, the executive vice president owned 74,430 shares of the company’s stock, valued at $18,607,500. This represents a 30.53% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. 0.06% of the stock is currently owned by corporate insiders.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: RINVOQ gains another European indication. The European Commission approved RINVOQ (upadacitinib) for children aged two and older with active polyarticular juvenile idiopathic arthritis who have not responded adequately to, or cannot tolerate, one or more DMARDs. The approval expands RINVOQ’s commercial reach and adds to its 11 approved EU indications, reinforcing the drug as a key growth driver for AbbVie. AbbVie Announces European Commission Approval of RINVOQ
• Positive Sentiment: AbbVie expands its AI drug-discovery strategy. AbbVie entered a multiyear collaboration with Iambic to use the company’s AI platform to identify and develop small-molecule therapies in immunology, neuroscience and oncology. The partnership could improve discovery efficiency and diversify AbbVie’s long-term pipeline, although any financial benefits are likely to take years to materialize. AbbVie and Iambic Announce Collaboration
• Positive Sentiment: Allergan Aesthetics launched AA Signature: SKIN360 in the U.S. The multimodal consultation program is intended to help providers address patients’ broader aesthetic goals and could support engagement across AbbVie’s aesthetics portfolio. The near-term earnings impact is not specified. Allergan Aesthetics Debuts AA Signature
• Neutral Sentiment: Recent commentary continues to highlight AbbVie’s dividend appeal and second-quarter results, which exceeded analyst expectations for both earnings and revenue. These reports support the stock’s defensive investment case, but largely reiterate previously reported information rather than provide a new catalyst. AbbVie vs. Pfizer

AbbVie Company Profile

AbbVie Inc (NYSE: ABBV) is a global biopharmaceutical company that discovers, develops and commercializes medicines across immunology, oncology, neuroscience, eye care, aesthetics and other specialty areas. The company was established in 2013 after separating from Abbott Laboratories, which retained Abbott’s diversified medical products and diagnostics businesses while AbbVie focused on research-based pharmaceuticals.

AbbVie’s immunology portfolio includes Skyrizi (risankizumab) and Rinvoq (upadacitinib), which are used to treat several inflammatory conditions.